Medicine
Relistor 150 mg tablet
Relistor 150 mg tablet is a prescription medicine containing Methylnaltrexone for oral use, marketed by Salix Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Store at up to 25°C (77°F), excursions permitted to 15° to 30°C…
Key facts
- Active ingredient (INN)
- Methylnaltrexone
- Brand
- Relistor
- Strength
- 150 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 bottle, 90 tablets
- Marketing authorisation holder
- Salix Pharmaceuticals
- Manufacturer
- Salix Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Store at up to 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F). Injection Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F). Protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A06AH01 Methylnaltrexone
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 August 2008
- Identifiers
- RxCUI 979113, 979115, 1244060 +5DailyMed set ID c488fb7c-0a5b-487c-b452-996809d1cb99NDC 65649-150Application NDA208271
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 6 tablet in 1 bottle | 65649-150-06 | Salix Pharmaceuticals | 19 July 2016 |
| 90 tablet in 1 bottle | 65649-150-90 | Salix Pharmaceuticals | 19 July 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Methylnaltrexone
Clinical summary
Methylnaltrexone is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment, among other approved uses. MedsAcross supplies Methylnaltrexone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MethylnaltrexoneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Relistor prescribing information (Salix Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Relistor: European public assessment report (EPAR) · European Medicines Agency
Need Relistor 150 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.